Infl ammatory Bowel Disease (IBD) encompasses two major chronic gastrointestinal diseases of unknown origin: ulcerative colitis (UC) and Crohn’s disease (CD). UC solely aff ects the colon, whereas CD can involve any component of the gastrointestinal tract from the oral cavity to the anus. In 2004, an estimated 1.4 million persons in the United States and 2.2 million persons in Europe suff ered from these diseases.1 The incidence of IBD has been increasing over the years, which for UC varies greatly between 0.5 and 24.5/105 inhabitants, and for CD varies between 0.1 and 16/105 inhabitants worldwide.2, 3 The prevalence rates of IBD reach up to 396/105 inhabitants.3

, , , , ,
Financial support for printing this thesis was kindly given by: Pentax Nederland B.V., Ferring B.V., ABBOTT Immunology, Tramedico B.V., Olympus Nederland BV, Crohn en Colitis Vereniging Nederland, AstraZeneca BV, Abbott Products B.V, Zambon Nederland B.V., Dr. Falk Pharma Benelux B.V., J.E. Jurriaanse stichting, de Nederlandse Vereniging voor Gastroenterologie , and the department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam
E.J. Kuipers (Ernst)
Erasmus University Rotterdam
Erasmus MC: University Medical Center Rotterdam

Baars, J. (2010, November 5). Complications of inflammatory bowel disease revisted. Retrieved from